Allos (ALOS3) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
17 Dec, 2025Executive summary
Achieved strong operational and financial results in 2024, with total sales reaching R$40.2 billion, up 7.7–8.6% year-over-year, and high occupancy rates at 96.8%.
FFO grew 29% to R$1.4 billion, with FFO per share up 40.8%, driven by share buybacks and operational improvements.
EBITDA rose 7.3–12.4% to R$2.0 billion, with a margin of 73.8–77.4%.
R$1.8 billion returned to shareholders via dividends and buybacks, representing a 19% yield.
1,130 new lease contracts signed and 61.7k sqm leased in 2024.
Financial highlights
Net revenue for 2024 was R$2,706 million, up 7.0% year-over-year; 4Q24 net revenue was R$825 million, up 8.6–9% from 4Q23.
Adjusted EBITDA for 4Q24 was R$638.5 million (77.4% margin), up 12.4% from 4Q23.
FFO for 4Q24 was R$467.7 million, up 23% year-over-year; FFO margin improved by 664 bps to 56.7%.
Capex in 2024 totaled R$539.1 million, focused on maintenance, renovations, and innovation.
Net income for 2024 was R$698.5 million, down 79.4% due to non-recurring items in the prior year.
Outlook and guidance
2025 EBITDA guidance set at R$2,070–2,150 million, implying 8% growth at the midpoint over 2024 proforma.
Capex guidance for 2025 is R$450–550 million, with continued investment in portfolio upgrades and technology.
Minimum 50% of FFO to be distributed to shareholders via dividends or buybacks.
Latest events from Allos
- FFO up 41.1% YoY, net income R$326.1M, and R$1.1B returned to shareholders.ALOS3
Q2 20242 Feb 2026 - FFO, revenue, and sales surged, with strong operational and capital allocation performance.ALOS3
Q3 202413 Jan 2026 - Revenue and NOI grew, with digital expansion and high occupancy driving future gains.ALOS3
Q2 202523 Nov 2025 - Revenue, EBITDA, and FFO per share rose, with net income up 286.8% year-over-year.ALOS3
Q1 202518 Nov 2025 - Sales, NOI, and dividends surged, driven by efficiency gains and strong cash flow.ALOS3
Q3 202515 Nov 2025